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Abstract
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Background—DNA delivery systems, which transport exogenous DNA to cells, have
applications that include gene therapy, tissue engineering and medical devices. Although the
cationic nonviral DNA carrier polyethyleneimine (PEI) has been widely studied, the molecular
factors and pathways underlying PEI-mediated DNA transfer remain largely unknown, preventing
the design of more efficient delivery systems.
Methods—HEK 293 T cells were treated with polyplexes formed with PEI and pEGFPLuc
encoding for green fluorescent protein (GFP). Transfected cells expressing GFP were flowseparated from treated, untransfected cells. Gene expression profiles were obtained using
Affymetrix HG-U133 2.0 microarrays and differentially expressed genes were identified using R/
Bioconductor. Gene network analysis using EGAN (exploratory gene association network)
bioinformatics tools was then used to find interaction among genes and enriched gene ontology
(GO) terms related to transfection. Genes identified by this method were perturbed using
pharmacologic activators or inhibitors to assess their effect on DNA transfer.
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Results—Microarray analysis comparing transfected cells to untransfected cells revealed 215
genes to be differentially expressed, with the majority enriched to GO processes including
metabolism, response to stimulus, cell cycle, biological regulation and cellular component
organization or biogenesis pathways. Gene network analysis revealed a coordinated induction of
RAP1A, SCG5, PGAP1, ATF3 and NEB genes implicated in cell stress, cell cycle and cytoskeletal
processes. Altering pathways with pharmacologic agents confirmed the potential role of RAP1A,
SCG5 and ATF3 in transfection.
Conclusions—Microarray and gene network analyses of the sorted, transfected cell population
can identify potential mediators of transfection, providing a basis for the design of improved
delivery systems.
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The design of efficient nonviral gene delivery systems offers potential uses in applications
such as gene therapy, tissue engineering, regenerative medicine, and medical devices.
Nonviral gene delivery involves the delivery of exogenous gene(s) to cells, typically
facilitated by the electrostatic complexation of the gene as plasmid DNA with a nonviral
vector such as the commonly used cationic polyethyleneimine (PEI) polymer [1–3].
However, the lack of efficacy of nonviral delivery systems prevents their clinical use. Much
emphasis has been placed on increasing transfection efficiency through the physiochemical
modification of the PEI vectors to overcome barriers [4–7] or to exploit genes identified by
gene profiling [8]; these studies have resulted in limited success and prompted investigations
into identifying the mechanisms of PEI transfection. An entire new field of polymer
genomics has emerged aiming to investigate the effect of polymer vectors, commonly used
for drug and DNA delivery, on endogenous gene expression profiles using high-throughput
techniques such as microarrays [9]. Microarray analysis has been performed to investigate
the toxicogenomics of nonviral vectors used for gene delivery, including PEI [10–13].
However, in these previous studies, the objective was to treat the cells with a vector (often
not complexed with DNA) to observe the associated gene expression profiles and cellular
responses, in particular cytotoxicity and apoptosis [14].
Although previous studies investigated cell, transgene, DNA carrier and time dependencies
on the endogenous cellular gene expression profile [11,13,15,16], there was no isolation of
transfected cells from untransfected cells, potentially masking information related to
successful DNA transfer. Previously, we have identified gene expression profiles of an
isolated transfected cell population. For those studies, HEK 293 T cells were transfected
with lipoplexes delivering a plasmid encoding green fluorescent protein (GFP) gene [17].
Flow cytometric separation and microarray analysis of transgene expressing cells (GFP+)
from treated but untransfected (GFP− ) cell populations revealed HSPA6 and RAP1A genes
as being up-regulated in GFP + cells compared to GFP− cells [17]. The activation of these
genes before the delivery of lipoplexes resulted in up to 2.5-fold increased transfection [17].
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In the present study, we expand our approach, extending our analysis to PEI, a widely used
nonviral vector that has been shown to demonstrate in vitro [18,19] and in vivo transfection
[13,20]. In addition, PEI may transfect cells using different pathways than lipoplexes [21–
24], which could be expounded through microarray analysis. We used microarray analysis to
identify differentially expressed genes between GFP+, GFP− and Untreated HEK 293 T
cells that occur after PEI-mediated DNA delivery. Gene ontology (GO) analysis grouped
these gene expression profiles into corresponding cellular processes. Furthermore,
Exploratory Gene Association Network (EGAN) analysis showed interacting networks
among genes and processes related to transfection. Transfection experiments, in the presence
or absence of pharmacologic activators or inhibitors, further implicated the role of these
genes in nonviral gene delivery and demonstrated an alternative approach to enhancing
transfection through the priming of cells. With increased understanding of endogenous
cellular mechanisms that occur during DNA transfer, more efficient nonviral gene delivery
systems can be designed to move this technology into therapeutic applications.
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Cell culture and plasmid preparation
Human embryonic epithelial kidney HEK 293 T cells (ATCC, Manassas, VA, USA) were
cultured in T-75 flasks in Dulbecco’s modified Eagle’s medium (Gibco/Invitrogen,
Carlsbad, CA, USA) containing 4.5 g/l glucose, supplemented with 10% fetal bovine serum
(Gibco), 2 mM L-glutamine (Gibco) and 100 units/ml of penicillin (Gibco) and maintained
at 37ºC in a humidified 5% CO2 atmosphere. For seeding, cells were dissociated at
confluency with 1 mM ethylenediaminetetraacetic acid (EDTA) and viable cells were
counted using a hemocytometer and trypan blue dye exclusion assay. For all transfection
experiments, plasmid pEGFPLuc, which encodes for both the enhanced green fluorescent
protein (EGFP) and firefly luciferase protein under the direction of a cytomegalovirus
(CMV) promoter (Clontech, Mountain View, CA, USA), was used. Plasmids were purified
from bacteria culture using Qiagen (Valencia, CA, USA) reagents and stored in Tris-EDTA
(TE) buffer at −20°C until ready for use.
Transfection optimization
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Branched 25 kDa PEI (Sigma-Aldrich, St Louis, MO, USA) was dialyzed with 10 000
MWCO Slide-A-Lyzer against ddH2O, lyophilized, dissolved in TE buffer at 1 mg/ml and
stored at −20 °C. Polyplexes were formed in 1 × Tris-buffered saline solution by dropwise
addition of PEI solution to plasmid DNA (pDNA) solution, briefly vortexed for 10 s, and
incubated for 15 min at room temperature. Polyplexes were formed and delivered to
adherent cells in serum-containing medium 18 h after cell seeding. Polyplexes were not
removed for the duration of the study. Transfection was optimized by varying the nitrogen to
phosphate ratio (N:P) and the amount of DNA and found to be optimal for high transfection
and low cytotoxicity at N:P of 20 and 0.25 μg/cm2 of pDNA (Figure S1).
Transfection for flow cytometry
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Cells were seeded at a density of 3.36 × 106 cells/flask into multiple T-75 flasks. Polyplexes
were formed and delivered to adherent cells as described in transfection optimization above.
Twenty-four hours after addition of polyplexes, cells were dissociated with the addition of
trypsin-EDTA. Cells were pooled, counted, and concentrated between 2 and 5 million cells
per ml in 1 × phosphate-buffered-saline and placed on ice. Next, cells were sorted by
fluorescence-activated cell sorting (FACS) into GFP + and GFP− populations, as described
previously [17], using a B-D FACSVantage SE three-laser, high speed cell sorter
(University of Nebraska-Lincoln Center for Biotechnology Flow Cytometry Core Facility)
equipped with a 530/15 nm SE laser. A live gate was set on the GFP + cell population in
forward scatter versus side scatter plot to remove cell debris or clumped cells from the sort.
A minimum of 2 × 106 cells for each population was collected (GFP+, GFP− ). Untreated
cells (i.e. those not treated with the polyplexes) were sorted in the same manner.
Transfection experiments were performed on three different days and, after cell sorting,
provided independent samples of GFP + (n = 3), GFP− (n = 3) and Untreated (n = 2); RNA
from these eight samples was used to hybridize to microarrays (see below).
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RNA extraction and quality check
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RNA extraction and quality check was performed as described previously [17]. After
obtaining sorted, independent populations of transfected cells (GFP+; n = 3), untransfected
cells (GFP− ; n = 3) and control cells (Untreated; n = 2), total RNA was Trizol extracted and
further purified using a RNeasy column (Qiagen) to achieve 260/280 ratio greater than 2.0
(data not shown) on Nanodrop 2000 (Thermo Scientific, West Palm Beach, FL, USA). The
quality of purified RNA was assessed using a RNA 6000 Nano LabChip on an Agilent
BioAnalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA) and then used for
microarray analysis (see below).
Microarray hybridization
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Purified RNA was reverse transcribed to cDNA and hybridized to Affymetrix GeneChip
Human Genome U133 Plus 2.0 Arrays (Affymetrix, Santa Clara, CA, USA) overnight at 45
°C. After streptavidin-phycoerythrin conjugate staining, expression data were read with the
GeneChip Scanner 3000 7G (Affymetrix). Affymetrix GeneChip Operating Software
(GCOS, version 1.3) was used for washing, scanning and basic data analysis, including
calculation of absolute values and normalization of the data with respect to internal
standards. A total of eight microarrays were used: three for GFP + samples, three for GFP−
samples and two for Untreated samples.
Microarray analysis
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Each microarray provides 11 independent measures of gene expression (n = 11) for over 47
000 transcripts and variants annotated for all known genes of the human genome.
Microarray expression data were background adjusted and normalized using Benjamini–
Hochberg statistical methods [25], and then the quality of expression data were tested using
R/Bioconductor with the AffyCoreTools library package (see Table S1 and Figures S2–S7).
Genes differentially expressed between GFP + and GFP−, GFP + and Untreated, and GFP−
and Untreated were determined using the linear models for microarrays package in R/
Bioconductor, with Benjamini–Hochberg false discovery rate (FDR) adjusted p-values [26].
All genes considered for further analyses (GO analysis or network analysis; see below) were
2.0-fold differentially expressed between gene profiles with FDR adjusted p-value less than
0.05. The gene expression data has been deposited at the NCBI Gene Expression Omnibus
under accession number GSE38422.
Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) validation
Microarray data validation was performed as described previously [17]. Two-stage,
singleplex qRT-PCR was used to confirm the expression of genes with greater than 5.0-fold
differential expression in all gene profile comparisons with FDR adjusted p-values of less
than 0.05 based on the microarray results. One microgram RNA was extracted from GFP +
and GFP− cells and reversed transcribed to cDNA using M-MLV reverse transcriptase and
random primers (Promega, Madison, WI, USA). PCR reaction mixtures were prepared using
1 μl of cDNA in a 2 × SYRBR Green PCR Master Mix 2X (Invitrogen), 2.5 μM forward
primer, 2.5 μM reverse primer and MilliQ-water (Millipore, Billerica, MA, USA) to a final
volume of 10 μl per reaction. RT-PCR was performed using a two-step temperature thermal
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cycling program consisting of 15 s at 95 °C and 60 s at 60°C for 40 cycles on an ABI 7300
System (Applied Biosystems, Foster City, CA, USA). GFP + and GFP− expression data
were normalized using geometric averaging [27] to the endogenous controls:
glyceraldehyde-3- phosphate dehydrogenase GAPD (NM_002046), hydroxymethylbilane
synthase HMBS (NM_000190) and beta-2-microglobulin B2M (NM_004048). For a list of
the gene-specific primers (IDT, Skokie, IL, USA) used, see the Supporting information
(Table S2). Validation experiments were performed in triplicate (n = 3) and data are reported
as the mean ± SE.
GO bioinformatic analysis
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EGAN analysis [28] was used to find enriched GO terms, using a standard one-tailed
Fisher’s exact test for enrichment value less than 1 × 10−5 considered statistically
significant. Gene expression data were loaded into EGAN using the default human genome
definition file for annotating probes of the microarray. Edge references and node colors were
set to HG-U133 Plus 2. Background adjustment was made based on the expression level of
all measured probes in the array. The raw microarray data indicating expression level, pvalue and probe annotation number for each comparison (GFP + versus GFP−, GFP− versus
Untreated, and GFP + versus Untreated) were loaded into EGAN. The summary method for
mapping data was set to maximum.
Gene network analysis
The EGAN bioinformatics tool [28] was also used to explore how the 215 genes identified
from the GFP + to GFP− comparison (Table S3) interact within a gene-and-pathwaynetwork, enriched (enrichment value <0.0001) to non-overlapping terms selected for
correlation to transfection (e.g. ‘positive regulation of cell cycle’ and ‘cell cycle’ overlap;
therefore, only the parent ‘cell cycle’ term was used). This type of analysis enables the
visualization of genes as they interact with each other and to selected processes, ontologies,
or pathways [GO, Medical Subject Headings (MeSH) and Kyoto Encyclopedia of Genes and
Genomes (KEGG) databases] [29–31].
Transfection in the presence or absence of pharmacologic agents
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Selected genes were further investigated for their effect on DNA transfer. These experiments
were performed as described previously [17]. Briefly, transfection studies were performed in
the presence and absence of pharmacological activators or inhibitors. Cells were seeded and
allowed to adhere, as explained for the optimization experiments above. Pharmacologic
agents were then added in concentrations and lengths of time known to activate or inhibit
genes [32–40]. Polyplexes were then prepared and delivered to the treated cells or to control
cells that received treatment of vehicle only. Transfection levels were assayed at 24 h postdelivery using a luciferase assay normalized to total protein concentration, and compared
with transfection levels in vehicle-only control cells. Pharmacologic activator and inhibitors
included 8CPT-2Me-cAMP [32], GGT1-298 [39], apomorphine [33], 5-aza-2′deoxycytidine [34], jasplakinolide [35], dexamethasone [36], SB203580 [40] (all from
Sigma-Aldrich) and phorbol 12-myristate 13-acetate (Fisher Scientific, Pittsburgh, PA,
USA) [37,38]. Statistical analysis was performed using Prism, version 5 (GraphPad, La
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Jolla, CA, USA). Comparative analyses were completed using Student’s t-test at a 95%
confidence level. Data are reported as the mean ± SEM.
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Results
Microarray data analysis
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Microarray analysis was used to compare the endogenous gene expression profiles of GFP +
and GFP− populations of HEK 293 T cells 24 h after delivery of PEI polyplexes for over 45
000 genes, with 11 independent measurements of the transcriptional activity of each gene.
Transfection conditions were optimized for both high transfection efficiency and low
cytotoxicity (Figure S1). Comparison of GFP + gene profiles with GFP− gene profiles
revealed 215 genes to be differentially expressed (Table S3) with 199 up-regulated genes
and 16 down-regulated genes (Figure 1). Among these genes, nine were at least 5.0-fold
differentially expressed between GFP + and GFP− gene profiles and of those, all upregulated: RAP1A, CHORDC1, ATF3, SCG5, NEB, WDR78, PGAP1, ACRC and IREB2
(Table 1). Differential comparison of GFP + with Untreated gene profiles can provide
insight into potential genes involved in polyplex delivery and transgene expression, whereas
comparison of GFP− and Untreated gene profiles may provide insight into ‘off-target’
effects of polyplex treatment that do not result in transgene expression; those results and
discussion are reported in the Supporting information (Document S1).
Validation of microarray transcriptional activity
To verify microarray performance in obtaining high-throughput gene expression, qRT-PCR
was used to validate microarray expression results for genes greater than 5.0-fold
differentially expressed between GFP + and GFP− cells with FDR adjusted p-values of less
than 0.05. Gene expression for RAP1A, CHORDC1, NEB, WDR78, PGAP1, ACRC, ATF3,
SCG5 and IREB2 was statistically up-regulated in the GFP + sample compared to GFP−
(Figure 2). These (qRT-PCR) results are consistent with the trend from the microarray
results, although relative expression levels were discrete likely as a result of the different
methods of measurement and normalization, a divergence commonly reported [41,42] and
reviewed elsewhere [43–45].
GO analysis
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The 215 genes differentially expressed in the GFP + versus GFP− gene profile comparison
(Table S3) were further studied for enriched GO biological processes using the EGAN
bioinformatics tool [28]. Of the 215 endogenous genes differentially expressed between
GFP + and GFP− cells, 102 genes were associated with one or more of five parent GO
processes (Table 2), including 83 genes in ‘GO: 0008152 metabolic process’, 50 genes in
‘GO: 0050896 response to stimulus’, 47 genes in ‘GO: 0007049 cell cycle’, 44 genes in
‘GO: 0065007 biological regulation’ and 31 genes in ‘GO: 0071840 cellular component
organization or biogenesis’. Many genes were represented in more than one of the parent
GO processes (Table 2). For example, RAP1A and ATF3 genes were both found to be
involved in three parent GO processes: ‘metabolic process’, ‘response to stimulus’ and
‘biological regulation’ (Table 2), with ATF3 additionally implicated in the ‘cell cycle’ GO
process. Genes that appeared in this analysis and were 5.0-fold differentially expressed
J Gene Med. Author manuscript; available in PMC 2014 July 30.
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between the GFP + and GFP− comparison (Table 1) were all represented in more than one
parent GO process (Table 2). Each parent GO process contained several child GO cellular
processes (Table 2).
Gene network and pathway analyses
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Next, the EGAN bioinformatics tool [28] was used to explore how the 215 genes from the
GFP + to GFP− comparison (Table S3) interact within a gene-and-pathway-network
selected specifically for terms known from literature to affect transfection [18,46–48],
described here as a transfection-network. Seventy-one of the 215 genes directly or indirectly
interacted with each particular process (Figure 3). For example, although RAP1A has a direct
interaction with ‘focal adhesion’ process, it has an indirect interaction to ‘cell adhesion’,
‘cytoskeleton organization’ and ‘active transport to cell nucleus’ through the ‘focal
adhesion’ process, the up-regulated ACTN2 gene and the up-regulated NEB gene (Figure 3).
Of the 71 genes that were found to belong to the transfection-network, 65 genes were upregulated and six genes were down-regulated (PRAF2, MYC, BMP2, SF3A2, G6PD) (Figure
3), suggesting that successful DNA transfer may act primarily through up-regulation of
genes rather than down-regulation. Among the nine genes identified as 5.0-fold
differentially expressed from the microarray analysis comparing GFP + to GFP− gene
profiles (Table 1), RAP1A, SCG5, PGAP1, ATF3 and NEB genes were discovered to have
interplay among genes and processes in four key cellular processes: (i) active transport to
cell nucleus; (ii) cellular response to stress; (iii) cytoskeletal signalling; and (iv) cell cycle.
The remaining four most highly up-regulated genes (CHORDC1, IREB2, ACRC, WDR78)
(Table 1) belonged to other GOs not enriched by this network analysis. For example,
CHORDC1 belongs to ‘regulation of response to stress’ (GO: 0080134) and IREB2 belongs
to ‘regulation of translation’ (GO: 0006417) [29]. ACRC and WDR78 have no known GO
processes.
Transfection in the presence or absence of pharmacologic agents
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To assess the usefulness of the microarray and network analyses in identifying genes as
potential molecular mechanisms of DNA transfer, selected genes were evaluated for their
role in DNA transfer using small-molecule activators or inhibitors (Table 3 and Figure 4)
[32–40,49,50]. Activating or inhibiting RAP1A, SCG5, ACRC, ATF3, ACTA1 and IREB2
genes with pharmacologic agents resulted in altered transfection levels compared to vehicle
controls. Studies that resulted in increased transfection were: activating RAP1A (+1.7-fold),
inhibiting SCG5 (+2.5-fold), activating ACRC (+1.6-fold) and activating IREB2 (+2.2-fold).
Studies that resulted in decreased transfection included: activating SCG5 (−1.2-fold),
activating ATF3 (−2.3-fold), inhibiting ACTA1 (−2.0-fold) and inhibiting IREB2 (−2.8-fold).

Discussion
Inefficient transgene expression continues to limit the efficacy of nonviral gene delivery
systems in clinical applications. A lack of direct information on the endogenous gene
expression profiles and intracellular signalling pathways that occur during successful DNA
transfer limits the optimal design of delivery vectors. Recent studies aimed to better
understand the DNA transfer process using particle tracking studies to identify putative
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barriers to DNA transfer, resulting in the common empirical approach of modifying the
DNA carrier to overcome one barrier for improved efficacy [51–63]. Other studies have
investigated the pharmacogenomics response of cells to the DNA carrier (alone and
complexed), thereby identifying genes involved in cytotoxicity and apoptosis, offering
targets for new vector design for improved safety [9–13,15,16,64]. However, even with
these efforts, the molecular mediators that facilitate successful DNA transfer remain unclear
[65], and the efficiency of nonviral gene delivery still remains below desired levels.
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In work previously conducted in our laboratory, FACS was used to separate transfected
(GFP+) cells from untransfected (GFP− ) cells, and then microarray analysis was used to
obtain separate gene profiles. RAP1A and HSPA6 were found to be overexpressed in the
GFP + population when compared with GFP− using lipoplex delivery [17]. Pharmacologic
studies, in which the target gene was activated and a change in transfection levels
determined, were used to reinforce the correlation of gene expression to the action of the
encoded protein [66] in transfection. Namely, increasing endogenous levels of RAP1A and
HSPA6 before treatment with lipoplexes resulted in up to 2.5-fold increased transfection
[17], thereby supporting a role for these genes as potential molecular mediators during DNA
transfer. However, the number of genes reported as differentially expressed between GFP +
and GFP− cells for lipoplexes [17] is in stark contrast to the research reported in the present
study for polyplexes (215 genes; Table S3), providing a molecular basis of evidence that
lipoplex and polyplex mechanisms of transfection may be different [11,21–24]. Even so, the
two genes reported as overexpressed in GFP + cells treated with lipoplexes [17] were also
overexpressed for polyplex-mediated transfection (Table S3), suggesting mechanisms that
may be common during successful DNA transfer, which could be exploited in the design of
new lipid- or polymer-based delivery systems. Of those two genes, RAP1A encodes for a
GTPase involved in integrin-mediated cell adhesion [67], which has been correlated with
transfection [68–71]. In addition, activating RAP1A before delivery of PEI complexes
increased transfection levels by 1.7-fold (Table 3), similar to our previous study [17], which
further implicates the importance of this gene in DNA transfer. HSPA6, heat shock 70-kDa
protein 6 (HSP70B’), is stress inducible to maintain cell viability and cytoprotection [72,73].
This gene has also been shown to be involved in the nuclear import of viral particles [74]
and thus could potentially be involved with the nuclear entry of nonviral DNA delivery
complexes, especially those containing viral DNA promoters (e.g. CMV). The remaining
identified genes in PEI-mediated transfection indicate endogenous gene expression that may
be DNA carrier specific [15], potentially as a result of differences in the hydrophobicity,
degradability, toxicity and routing kinetics of the complex [11,21–24].
Microarray, GO and network analyses
A combined microarray and GO analysis for GFP + compared with GFP− gene profiles
provided insight into the molecular mechanisms used during PEI-mediated DNA transfer.
Analyses showed that the 215 genes differentially expressed between GFP + and GFP− gene
profiles (Table S3) belonged to five GOs indicating activity in: (i) cell stress (metabolic
process, response to stimulus, biological regulation); (ii) the cell cycle (metabolic process,
cell cycle, biological regulation); and (iii) cytoskeletal organization (metabolic process,
biological regulation, cellular component organization or biosynthesis) (Table 2). Similar
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biological processes including cell stress, cell cycle and cytoskeletal organization have been
previously reported to be induced by PEI polyplexes in vivo [13], and by PEI, chitosan and
PAMAM polyplexes in vitro [11,18,75]. Our findings identify the specific genes related to
those processes involved in successful DNA transfer. Network analysis revealed a
coordinated induction of RAP1A, SCG5, PGAP1, ATF3 and NEB genes implicated in
processes known to affect transfection (cell stress, cell cycle, and cytoskeletal processes)
[18,46–48] (Figure 3 and Table 1) and indicate that these genes play a role in successful
DNA transfer. Further studies involving pharmacologic activation or inhibition suggest a
role for the gene in transfection for the RAP1A, SCG5 and ATF3 genes (from the network
analysis) and the ACRC, ACTA1 and IREB2 genes (from microarray analysis). A literature
review suggests a role for these six genes in cell stress, cell cycle or cytoskeletal activity
(mechanisms correlated with transfection) [76–83], as discussed below.
Cell stress
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Several of the enriched GO terms indicated that genes related to cell stress activity were
overexpressed in transfected cells, such as nucleic acid repair, response to DNA damage
stimulus, cellular response to stress and cell cycle arrest (Table 2). Cells have a proposed set
of immediate early genes that are induced in response to stress signals irrespective of cell
type or nature of stressor. Godbey et al. [18] proposed two toxicities associated with
polyplex treatment: immediate toxic shock to free polymer membrane destabilization and a
delayed (> 8 h) toxicity as a result of the cellular processing of polyplexes. The optimal
transfection condition used in the present study was at an N:P of 20 (Figure S1), a condition
where unbound PEI may be present, which has been shown to greatly impact transfection
levels concomitant with cell stress [84–86]. The present study may identify specific genes
involved in the mechanisms by which free PEI can enhance transfection by affecting cell
stress, including the ATF3 gene; the up-regulation of ATF3 in GFP + cells (Table 1)
indicates sustained cellular stress possibly as a result of the nondegradable nature of PEI
[87]. Alternatively, ATF3 may be up-regulated in response to the presence of foreign DNA
because ATF3 has been reported to be overexpressed immediately after viral infection
[88,89]. Up-regulation of ATF3 (Table 1) suggests a common cellular response to DNA
delivery systems, possibly as a cell mechanism preventing the further uptake of foreign
DNA because activating ATF3 [35] in cells before the delivery of polyplexes resulted in
drastically reduced transfection levels (Table 3). Taken together, gene activity that results in
increased stress and DNA damage proteins or DNA repair proteins was observed in GFP +
cells compared to GFP− (Tables 1 and 2; see also Supporting information, Table S3),
suggesting that these genes play a role in PEI-mediated transfection.
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Cell cycle
Cell cycle and cell proliferation are known to affect transfection [46,64], which is consistent
with our results showing many of the parent GO terms related to the cell cycle (Table 2).
Cellular stress and DNA damage often induce cell cycle checkpoints in the presence of
DNA damage through sensor, transducer and effector concerted protein efforts [75]. The
presence of cell cycle genes in the GFP + versus GFP− comparison appears consistent with
this fact because cell stress was reported concomitant to cell cycle activity (Table 2). One
gene implicated in cell growth and proliferation, and also cell stress, was the heat shockJ Gene Med. Author manuscript; available in PMC 2014 July 30.
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inducible SCG5 gene, which was 5.3-fold up-regulated in GFP + cells (Table 1) [49,90].
SCG5 is a chaperone protein required for proprotein convertase 2 (PC2), a hormone
implicated in stress signalling [90]. Inhibiting SCG5 activity [33] before the delivery of
complexes resulted in a 2.5-fold increase in transfection (Table 3). Genes involved in
reducing cell stress were important to transfection (above) and inhibiting the hormone
signalling gene SCG5 may mask stress incurred by polyplexes, allowing for enhanced
transfection. Finally, increased cell cycle activity requires increased energy levels, which is
consistent with our results suggesting an increase in tricarboxylic acid (Krebs) cycle activity
by up-regulation of IREB2 (Table 1) [82,83]. Increasing IREB2 activity (Table 3) [37,38]
before delivery of complexes resulted in 2.2-fold increase in transfection, whereas inhibiting
IREB2 decreased transfection by 2.8-fold, confirming reports correlating cell cycle and
transfection [46,64]. It should also be noted that cells were not synced to more closely
mimic conditions found in vivo. In addition, data were differentially compared to eliminate
intrinsic metabolic noise (e.g. basal levels of cell cycle or metabolism genes) in our gene
expression analysis [91]. Taken together, these data suggest molecular mediators of the cell
cycle that are important for successful PEI polyplex-mediated DNA transfer.
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Cytoskeletal signalling and nuclear localization
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The roles of cytoskeletal and transport processes have been strongly correlated with
transfection [47,48,71] and, to facilitate DNA transfer, the cytoskeletal network may be
modified. In the present study, ACTA1, which is a major component of the cell cytoskeleton,
was 4.46-fold up-regulated in GFP + versus GFP− gene profiles (Table S3) [92]. Inhibiting
ACTA1 [36] before the delivery of complexes resulted in 2.0-fold reduced transfection
(Table 3), reinforcing the important role of cytoskeletal components in DNA delivery
[47,48]. Finally, the delivered DNA must localize within the nucleus, which is a critical step
for transgene expression [93]. Nuclear localization signals (NLSs) can help this process and
may explain the 5.95-fold up-regulation of ACRC (Table 1). ACRC gene codes for an acid
repeat containing nuclear protein with a deduced nuclear localization potential because it
contains eight bipartite NLSs in the C-terminal region of the protein [76,77]. This gene may
facilitate nuclear localization or entry, as suggested by the 1.6-fold increase in transfection
as a result of activating ACRC [34] before the delivery of complexes (Table 3). The findings
from the present study have identified specific genes involved in cytoskeletal signalling and
nuclear localization processes that may be utilized during DNA transfer.
For nonviral gene delivery techniques to have therapeutic application, transfection efficiency
and a direct understanding of the transfection process must be increased. The present study
has identified genes and biological processes specific to successful DNA transfer, by
analyzing gene expression profiles of transfected, untransfected and Untreated cells,
separately. Subsequently, the ability of selected genes to affect transfection was confirmed
by pharmacologic studies. Mediators of cell stress (DNA damage or repair proteins), the cell
cycle and cytoskeletal signalling were shown to greatly influence transfection. Future
studies should consider the action of the encoded proteins in these pathways as they
influence DNA transfer with respect to other vectors, cell types, DNA and time points.
Additionally, these genes should be considered in the design of new carriers, the
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modification of existing DNA carriers and/or in cell priming to achieve transfection levels
that can advance therapeutic applications.
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Figure 1.

The number of genes differentially expressed for transfected (GFP+), untransfected (GFP− )
or Untreated cell comparisons 24 h after delivery of polyplexes to HEK 293 T cells.
Summary data represent up-regulated (black bars) or down-regulated (grey bars) genes with
differential expression greater than 2.0-fold with significance (p <0.05) from hybridization
experiments using human cDNA microarrays containing over 45 000 probes. Untreated cells
were not treated with polyplexes.
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Figure 2.

Quantitative RT-PCR reactions confirm gene changes measured by the microarrays for
transfected (GFP+) samples (black bars) and untransfected (GFP− ) samples (grey bars).
GFP + and GFP− expression was normalized to endogenous housekeeping controls (see
Materials and methods) to provide relative expression of each measured gene. Data are
reported as the mean ± SEM (n = 3) and significant changes between GFP + and GFP−
expression are indicated by asterisks (*p <0.05 or **p <0.01).
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Multiple processes and pathways were identified by EGAN linking genes (differentially
expressed between transfected cells (GFP+) and untransfected (GFP− ) cells 24 h after
treatment with polyplexes) to processes known to affect transfection. These linkages
represent association of genes with GO, MESH and KEGG terms found to be highly
enriched. Processes or pathways can be seen to be specifically up-regulated or downregulated by genes in green or blue, respectively. All line colors, node sizes and node colors
are default settings of EGAN for the type of interaction, significance and relative expression
[28].
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Figure 4.

HEK 293 T cells were treated with pharmacologic agent (Treated; black bars) or treated
only with the vehicle used to deliver the pharmacologic agent (Control+; open bars) to
activate or inhibit RAP1A, SCG5, ACRC, ATF3, ACTA1 or IREB2 genes (for conditions, see
Table 3). Polyplexes were then delivered and transfection levels were assayed (see Materials
and methods) after 24 h. Data are reported as the mean ±SEM (n = 3) and significant
changes between treated and vehicle-only transfection levels are indicated by asterisks (**p
<0.01).
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Genes greater than 5.0-fold differentially expressed in the GFP + versus GFP− gene profile comparison

NIH-PA Author Manuscript

Differential expression

p-valuea

Encodes for a GTPase implicated in integrin-mediated cell adhesion and focal
adhesions [94]

12.58

1.23 × 104

CHORDC1

Cysteine and histidine-rich domain (CHORD) containing 1 encodes for the heat shock
inducible Morgana/CHP-1 protein [82]

10.38

8.15 × 106

NEB

Nebulin has several domains that may play essential roles in cell migration, motility,
cytoskeletal dynamics, and focal adhesions [95,96]

7.81

1.13 × 105

WDR78

Encodes for the WD repeat domain 78 protein with high lipid raft affinity [79]

6.96

1.84 × 105

PGAP1

Responsible for anchoring the glycolipid GPI (glycosylphosphatidylinositol) to proteins
which are then transported and anchored at the cell membrane, especially within lipid
rafts [80,81]

6.33

8.52 × 104

ACRC

Contains 8 bipartite NLSs and is found to localize with chromatin [77]

5.95

6.36 × 104

ATF3

Activating transcription factor 3, is an immediate-early gene that acts as a repressor of
ATF promoter sites and is inducible through the NF-kB and JNK/SAPK signal
transduction pathway [35,89,97]

5.34

2.44 × 104

SCG5

Secretogranin V (7B2 protein) encodes for the stress inducible sorting chaperone that
activates prohormone convertase PC2 carboxy terminated protease activity upon
binding [49,91,98,99]

5.30

1.13 × 105

IREB2

Iron-responsive element binding protein 2 is activated in response to oxidative stress
and energy metabolism [83,84]

5.30

2.44 × 104

Gene name

Gene role

RAP1A

a

Adjusted for FDR.
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Table 2

NIH-PA Author Manuscript

Statistically over-represented GO terms for GFP + versus GFP− gene profile comparison
GO pathway interaction

Number of genes

Parent GO: 0008152 metabolic
process

p-value

83

NIH-PA Author Manuscript

DNA metabolic process

1.90 × 10−10

DNA repair

4.60 × 10−9

Macromolecule catabolic process

1.27 × 10−8

Transcription from RNA polymerase
II promoter

4.26 × 10−8

Protein amino acid phosphorylation

6.73 × 10−8

DNA replication

1.33 × 10−7

Cellular catabolic process

1.37 × 10−7

RNA processing

1.53 × 10−6

Cellular macromolecule catabolic
process

2.32 × 10−6

mRNA metabolic process

4.04 × 10−6

Carbohydrate metabolic process

7.97 × 10−6

Amine metabolic process

8.42 × 10−6

Parent GO: 0050896 response to
stimulus

2.58 × 10−11
10−10

Cellular response to stress

1.30 ×

DNA repair

4.60 × 10−9

Response to organic substance

2.33 × 10−7

Response to protein stimulus

4.38 × 10−7

Response to unfolded protein

6.00 × 10−7

ACTA1, ALB, ALDH8A1, ATF3, ATXN1, BATF3, BMP2,
C2orf66, CHORDC1, CLK1, CSNK1A1, CYP2E1, DDB2,
DDIT3, DDIT4, DNAJB1, DNAJB6, DTL, ERP44, FUBP1,
G6PD, GADD45A, GORAB, GTF2H1, HBS1L, HMOX1,
HSPA6, KIN, MBD4, MDM2, MOGS, MXD1, MYC,
NR1H3, PGAP1, PHIP, POLQ, PPIL3, PPM1D, PSPC1,
PVT1, PYGM, RAD52, RAP1A, RAPGEF2, REV3L,
RPP30, SAT1, TYMS, XRN1

47

NIH-PA Author Manuscript

Cell cycle

2.70 × 10−15

Regulation of cell cycle

4.66 × 10−12

Cell cycle process

7.46 × 10−9

Negative regulation of cell cycle

3.79 × 10−7

Cell cycle phase

4.24 × 10−7

Cell cycle arrest

4.60 × 10−7

Mitotic cell cycle

3.14 × 10−6

Parent GO: 0065007 biological
regulation

MOGS, SF3A2, BCKDK, G6PD, BMP2, MYC, ATXN1,
RSL1D1, MBD4, LYG1, RLIM, PPM1D, SIK3, RPP30,
WNK4, GORAB, PVT1, BACE1, TYMS, CDT1, OVGP1,
CLK1, PPIL3, DTL, CEL, KHDRBS1, REV3L, KIN,
CSNK1A1, DDIT4, CDK12, DDB2, DNAJB6, CTH,
GADD45A, CLK4, POLQ, RBM15, RAPGEF2, TTBK2,
DNAJB1, MXD1, RAD52, AOC3, SAT1, CYP2E1, TARS,
TPH1, ZNF473, XRN1, MCM9, MAP6D1, PHIP, HMOX1,
HDAC8, HBS1L, SRSF5, PSPC1, CHD2, PYGM, AMY1A,
AMY1B, AMY2B, AMY2A, AMY1C, RBM25, ALDH8A1,
UBR1, DDR2, PLK2, GTF2H1, DDIT3, NR1H3, FUBP1,
MDM2, MTHFD2L, ACTA1, TEX14, IREB2, ATF3, PGAP1,
CHORDC1, RAP1A

50

Response to DNA damage stimulus

Parent GO: 0007049 cell cycle

Associated genes

NR1H3, DDB2, MYC, MXD1, DNAJB6, PGAP1, C2ORF66,
MOGS, RPP30, PVT1, XRN1, CLK1, PPIL3, FUBP1,
DDIT3, GTP2H1, ATF3, BATF3, C1ORF103, SAT1, PSPC1,
DDIT4, ID3, SERTAD1, SRSF5, SF3A2, RBM25, DTL,
CKAP2, SEPT7P2, BMP2, SESN2, GORAB, MDM2,
PPM1D, GADD45A, KHDRBS1, CDT1, PHIP, PLK2,
CSNK1A1, ACTA1, PPP5C, CHORDC1, NAALAD2,
SYCE2, RAD52

44

Negative regulation of nucleobase,
nucleoside, nucleotide and nucleic
acid metabolic process

1.12 × 10−6

Negative regulation of nitrogen
compound metabolic process

1.23 × 10−6

Negative regulation of macromolecule
biosynthetic process

1.98 × 10−6

MOGS, G6PD, BMP2, MYC, BATF3, ATXN1, SERTAD1,
RLIM, PPM1D, RPP30, GORAB, PVT1, CDT1, CLK1,
PPIL3, KHDRBS1, DDIT4, DDB2, DNAJB6, CTH, RBM15,
RAPGEF2, DNAJB1, MXD1, SAT1, XRN1, PHIP, HMOX1,
HDAC8, HBS1L, PSPC1, CHD2, ALDH8A1, DDR2,
GTF2H1, DDIT3, NR1H3, FUBP1, MDM2, IREB2, ATF3,
PGAP1, RAP1A, C2orf66
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GO pathway interaction

Number of genes

p-value

NIH-PA Author Manuscript

Regulation of transcription from RNA
polymerase II promoter

2.10 ×

Negative regulation of cellular
biosynthetic process

2.58 × 10−6

Negative regulation of biosynthetic
process

2.98 × 10−6

Negative regulation of cellular
metabolic process

3.54 × 10−6

Negative regulation of transcription

3.58 × 10−6

Negative regulation of macromolecule
metabolic process

4.33 × 10−6

Negative regulation of metabolic
process

8.69 × 10−6

Negative regulation of gene expression

8.69 × 10−6

Parent GO: 0071840 cellular
component organization or biogenesis

Associated genes

10−6

31

Macromolecular complex subunit
organization

8.17 × 10−7

Macromolecular complex assembly

2.30 × 10−6

NIH-PA Author Manuscript

PPIL3, CLK1, XRN1, MYC, RPP30, MOGS, PGAP1,
C2ORF66, DDB2, NR1H3, MXD1, DNAJB6, PVT1, FUBP1,
GTF2H1, PPP5C, CHORDC1, NAALAD2, HMOX1, LPXN,
HIST1H2BD, SRSF5, MAP6D1, SF3A2, RBM25, ATL2,
ACTN2, CTH, MDM2, PPM1D, GORAB

Number of genes associated with each parent GO process are shown. Associated genes are shown in bold if they are repeated in more than one
parent GO processes and underlined if differential expression is greater than 5.0-fold.
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40 mM; 1 h
Heat shockd
10 μM; no removal

↓ [39]
↑ [49]
↓ [33]

GGT1-298

N/A

Apomorphine

200 nM; no removal
5 μM; 0.5 h

↑ [35]
↓ [40]

PMA

SB203580
500 pM; 0.5 h
5 μM; 2 h
0.8 μM; 0.5 h

↓[36]
↑ [37,38]
↓ [50]

Jasplakinolide

DEX

PMA

ACTA1

IREB2

ATF3

10 μM; no removal

↑ [34]

AZA

ACRC

SCG5

DMSO

EtOH

DMSO

DMSO

DMSO

ddH2O

ddH20

N/A

DMSO

ddH2O

Vehicle (Control+)

−2.8

2.2

−2.0**

–c

−2.3**

1.6

2.5

−1.2

–c

1.7**

Transfection fold changeb

Cell cycle

Cytoskeletal

Cell stress

Cytoskeletal

cell stress and cytoseketal

Cell cycle,

Cell stress and cytoskeletal

Role(s)

<0.01).

For heat shock treatment, cells were held at 23 °C for 1 h, then 30 °C for 1 h, and then complexes were delivered before returning to an incubator at 37 °C. Transfection levels were measured 24 h after the
delivery of complexes to HEK 293 T cells. CPT, 8CPT-2Me-cAMP; AZA, 5-Aza-2′-deoxycytidine; DEX, dexamethasone; PMA, phorbol 12-myristate 13-acetate; DMSO, dimethyl sulfoxide; EtOH,
ethanol; ddH20, double distilled water; NA, not applicable. Data are reported as the mean (n = 3) and significant changes between treated and vehicle-only transfection levels are indicated by asterisks (**p

d

Condition was toxic to cells and therefore transfection levels could not be reported (data not shown).

c

b
A positive fold change represents increased transfection levels and a negative fold change represents decreased transfection levels comparing cells treated with pharmacologic agent to cells treated with
vehicle only (Control+) (Figure 4).

Effect of pharmacologic agent on gene or protein activity as reported in the literature: ↑, activation; ↓, inhibition.

a

20 μM; 2 h

↑ [32]

CPT

RAP1A

Treatment condition

Agent

Gene

Effecta

Transfection in the presence or absence of pharmacologic agents
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